CHRETO - A paradigm shift in mAb purification

Denmark · 5 Employees
PROTEIN A CAPTURE OFIMMUNOGLOBULINS IN SOLUTION: SKIP THE PROTEIN A COLUMN Our vision is that the CHRETO Technology™ will - radically improve the process efficiency of downstream processing of large biomolecules - increase yields in existing production, especially IVIG - bring more monoclonal antibody (mAb's) candidates to testing. - speed up initial clinical phases - result in better and more efficient treatment of diseases. We believe that CHRETO's Protein Purification Technology will bring a true revolution to bio-manufacturing, which has been sought by the industry for decennia. CHRETO was founded in 2010, as a spin out of Novozymes, by the inventor Jan Kyhse-Andersen and Torben Jørgensen to develop and commercialize a novel protein purification technology for bio-manufacturing. The company acquired in 2014 the rights to the original IP related to protein purification technology from Novozymes, DK. A prototype of the technology has been developed and thoroughly tested by industry experts and a leading biopharmaceutical company in Europe during 2014/16. The Technology is expected to be introduced late 2020 How does the CHRETO Technology for mAb purification: The purification process consists of three steps: catch, clean and collect. Catch. The DAP molecule reacts in solution with the feed stream containing the target molecule(s) e.g., an antibody. Clean. Impurities including HCP (host cell proteins) and DNA are removed followed by dissociation of the DAP-antibody complex and capture of DAP to a biotin support. Collect. The purified antibody is collected and the membrane cartridge is discharged. Benefits: - Process improvements on 30% - The cost for manufacturing material used in clinical trials is likely to be reduced by a factor of 20. INTERESTED? Contact us for more information: info@chreto.com

概述

国家 Denmark
成立时间 2010
总部 LejrVej 17, Vaerloese, DK DK-3500, DK
电话号码 +45 22 92 80 82
网站 http://www.chreto.com
LinkedIn http://www.linkedin.com/company/chreto
Twitter
Facebook
员工数 5
行业 research,
简介 PROTEIN A CAPTURE OFIMMUNOGLOBULINS IN SOLUTION: SKIP THE PROTEIN A COLUMN Our vision is that the CHRETO Technology™ will - radically improve the process efficiency of downstream processing of large biomolecules - increase yields in existing production, especially IVIG - bring more monoclonal antibody (mAb's) candidates to testing. - speed up initial clinical phases - result in better and more efficient treatment of diseases. We believe that CHRETO's Protein Purification Technology will bring a true revolution to bio-manufacturing, which has been sought by the industry for decennia. CHRETO was founded in 2010, as a spin out of Novozymes, by the inventor Jan Kyhse-Andersen and Torben Jørgensen to develop and commercialize a novel protein purification technology for bio-manufacturing. The company acquired in 2014 the rights to the original IP related to protein purification technology from Novozymes, DK. A prototype of the technology has been developed and thoroughly tested by industry experts and a leading biopharmaceutical company in Europe during 2014/16. The Technology is expected to be introduced late 2020 How does the CHRETO Technology for mAb purification: The purification process consists of three steps: catch, clean and collect. Catch. The DAP molecule reacts in solution with the feed stream containing the target molecule(s) e.g., an antibody. Clean. Impurities including HCP (host cell proteins) and DNA are removed followed by dissociation of the DAP-antibody complex and capture of DAP to a biotin support. Collect. The purified antibody is collected and the membrane cartridge is discharged. Benefits: - Process improvements on 30% - The cost for manufacturing material used in clinical trials is likely to be reduced by a factor of 20. INTERESTED? Contact us for more information: info@chreto.com

技术

Apache

Load Balancers

Typekit

Fonts

Varnish

Load Balancers

常见问题

CHRETO - A paradigm shift in mAb purification 在哪里?

CHRETO - A paradigm shift in mAb purification 的总部位于 LejrVej 17, Vaerloese, DK DK-3500, DK

CHRETO - A paradigm shift in mAb purification 的电话号码是多少?

CHRETO - A paradigm shift in mAb purification 的电话号码是 +45 22 92 80 82

CHRETO - A paradigm shift in mAb purification 的官方网站是什么?

CHRETO - A paradigm shift in mAb purification 的公司官方网站是 http://www.chreto.com

CHRETO - A paradigm shift in mAb purification 是做什么的?

CHRETO - A paradigm shift in mAb purification 的业务有哪些?

process improvement,monoclonal antibodies,bioprocessing,polyclonal antibodies

CHRETO - A paradigm shift in mAb purification 的年收入是多少?

CHRETO - A paradigm shift in mAb purification 的收入是 0美元

CHRETO - A paradigm shift in mAb purification 有多少员工?

CHRETO - A paradigm shift in mAb purification 有 5 名员工

CHRETO - A paradigm shift in mAb purification 属于哪个行业?

CHRETO - A paradigm shift in mAb purification 从事以下行业: research

CHRETO - A paradigm shift in mAb purification 使用什么技术?

CHRETO - A paradigm shift in mAb purification 使用的一些流行技术包括: Apache,Typekit,Varnish

如何联系 CHRETO - A paradigm shift in mAb purification?

CHRETO - A paradigm shift in mAb purification 联系信息: 电话号码:+45 22 92 80 82， 网站:http://www.chreto.com， 邮箱：jan***@***.com

CHRETO - A paradigm shift in mAb purification 的社交媒体链接是什么?

CHRETO - A paradigm shift in mAb purification 领英：http://www.linkedin.com/company/chreto,fackbook：,twitte:

CHRETO - A paradigm shift in mAb purification 是一家上市公司吗?

不是

CHRETO - A paradigm shift in mAb purification 的最后一轮融资是什么时候?

暂无最近投资信息

谁投资 CHRETO - A paradigm shift in mAb purification?

CHRETO - A paradigm shift in mAb purification 有 0 家投资者,包括 。

管理层

Jan Kyhse-Andersen

Founder & CEO

Ernst Meinjohanns

Protein and Process Manager

员工

外贸获客 查找关键决策人

10亿+海关交易数据，1.2亿企业数据，2亿+企业联系人数据，1000千万真实采购商。覆盖200+个国家及地区，95%外贸重点拓展市场，可根据行业、经营范围等多方位挖掘目标客户。
免费试用

Top-ranked on G2 Crowd

全球B2B企业库 海关贸易数据 展会采购数据

工作更少，成就更大，销售更聪明

查找更多 B2B 联系人，丰富并验证记录
Email Address

全球B2B企业库

海关贸易数据

展会采购数据

Top-ranked on G2 Crowd

OR
Sign Up with Google